Search results
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives Buy Rating from Chardan Capital
ETF DAILY NEWS· 4 days agoArrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued on Monday ...
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
Benzinga via Yahoo Finance· 6 days agoOn Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3...
Arrowhead fortifies position in tight Ionis race, with RNAi med lowering triglycerides in phase 3
FierceBiotech· 6 days agoArrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients...
Goldman starts Arrowhead at neutral, cites RNAi portfolio validation (NASDAQ:ARWR)
Seeking Alpha· 4 days agoGoldman Sachs initiated coverage of Arrowhead (ARWR) with a neutral rating. Read more here.
Instacart, Boston Beer upgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 4 days agoIt sees the stock as attractive at current levels. Goldman Sachs initiated coverage of Arrowhead ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoRNAi Therapeutics and Technology Market Worth USD 5.36 Billion by 2031 at 16.6% CAGR- Exclusive Report by InsightAce Analytic Pvt. Ltd. PR Newswire JERSEY CITY, N.J., June 4, 2024 JERSEY CITY, N.J., June 4, 2024 /PRNewswire/ -- InsightAce Analytic
Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab
MedPage Today· 6 days agoConsolidation treatment with durvalumab (Imfinzi) following concurrent chemoradiotherapy...
MDMA's Cardiac Safety Concerns; Entresto Generics; Heart Disease 'Older Than Moses'
MedPage Today· 5 days agoFDA reviewers questioned the cardiac safety of midomafetamine (MDMA), among other concerns raised ahead of an advisory committee meeting on a potential drug indication for post-traumatic stress ...
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday -...
Benzinga· 6 days agoArrowhead Pharmaceuticals, Inc . ARWR rose 8.9% to $24.99 as the company reported topline results from pivotal Phase 3 PALISADE study of investigational ...